SpringWorks Therapeutics Inc Market Cap ($3.54 Billion)
Market Cap & Net Worth: SpringWorks Therapeutics Inc (SWTX)
SpringWorks Therapeutics Inc market cap. SpringWorks Therapeutics Inc (NASDAQ:SWTX) has a market capitalization of $3.54 Billion ($3.54 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4298 globally and #1513 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SpringWorks Therapeutics Inc's stock price $46.99 by its total outstanding shares 75349000 (75.35 Million). Also see SpringWorks Therapeutics Inc (SWTX) cash flow conversion for how efficiently the company converts equity into cash flow.
SpringWorks Therapeutics Inc Market Cap History (2019–2025)
SpringWorks Therapeutics Inc market cap history from 2019 to 2025. Data shows growth from $2.90 Billion to $3.54 Billion (13.43% CAGR). Check SpringWorks Therapeutics Inc stock quote for real-time trading data and today's change.
Index Memberships
SpringWorks Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.14% | #115 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #501 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.19% | #73 of 263 |
Weight: SpringWorks Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
SpringWorks Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SpringWorks Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SpringWorks Therapeutics Inc (SWTX) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
14.21x
SpringWorks Therapeutics Inc's market cap is 14.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $5.46 Billion | $35.00 Million | -$44.24 Million | 156.12x | N/A |
| 2021 | $4.67 Billion | $35.00 Million | -$173.21 Million | 133.43x | N/A |
| 2022 | $1.96 Billion | $6.15 Million | -$274.16 Million | 318.83x | N/A |
| 2023 | $2.75 Billion | $5.45 Million | -$325.10 Million | 504.91x | N/A |
| 2024 | $2.72 Billion | $191.59 Million | -$258.13 Million | 14.21x | N/A |
Competitor Companies of SWTX by Market Capitalization
Companies near SpringWorks Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see SpringWorks Therapeutics Inc total assets for a full breakdown of the balance sheet.
Key companies related to SpringWorks Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of SpringWorks Therapeutics Inc (2019–2025)
Market capitalization of SpringWorks Therapeutics Inc from 2019 to today. Between 2019 and today, SpringWorks Therapeutics Inc's market cap moved from $2.90 Billion to $ 3.54 Billion, with a yearly change of 13.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.54 Billion | +30.06% |
| 2024 | $2.72 Billion | -1.01% |
| 2023 | $2.75 Billion | +40.33% |
| 2022 | $1.96 Billion | -58.03% |
| 2021 | $4.67 Billion | -14.53% |
| 2020 | $5.46 Billion | +88.41% |
| 2019 | $2.90 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 29th, 2026 the market cap of SpringWorks Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.54 Billion USD |
| MoneyControl | $3.54 Billion USD |
| MarketWatch | $3.54 Billion USD |
| marketcap.company | $3.54 Billion USD |
| Reuters | $3.54 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SpringWorks Therapeutics Inc
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor o… Read more